RxDoctor Payments Data

Roohi Faiyaz, MD

Hospitalist · Gainesville, GANPI 1609012111

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Boehringer Ingelheim at 39.6% of the total. Reporting peaked in 2023 at $127 and has fallen 82.0% since, to $23 in 2024.

$171in general payments, 2019–2025

Across 6 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$68
  • Pfizer$38
  • Laborie Medical Technologies Corp.$23
  • Novartis$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20
$173,668in research payments, 2019–2025

Across 43 payments — averaging $4038.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$74K
  • Acella Pharmaceuticals, LLC$29K
  • AstraZeneca$24K
  • Teva Pharmaceuticals USA, Inc.$20K
  • Novo Nordisk AS$15K
  • Avion Pharmaceuticals$11K
  • plus $882 from 1 others

What the payments were for

  • Food & beverage$171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$171 in reported general payments places this provider in the 55th percentile of 812 hospitalist providers in Georgia.

See all hospitalist providers in Georgia

Medicare billing

Part B allowed, 2024
$81,353
Medicare patients
300
Services billed
904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$7,987
Atorvastatin Calcium24$167
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$108
Pantoprazole Sodium11$45
Metoprolol Tartrate13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$7,98713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 812 hospitalist providers in Georgia.

Other hospitalist in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →